Department of Chemistry, Zhejiang University, Hangzhou, P. R. China.
Laboratory of Cancer Biology, Key Lab of Biotherapy in Zhejiang, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, P. R. China.
J Enzyme Inhib Med Chem. 2021 Dec;36(1):593-604. doi: 10.1080/14756366.2021.1875458.
Colorectal cancer (CRC) is a common malignant tumour of human digestive tract. The high mortality rate of CRC is closely related to the limitations of existing treatments. Thus, there is an urgent need to search for new anti-CRC agents. In this work, twenty novel coumarin-dithiocarbamate derivatives () were designed, synthesized and evaluated . The results suggest that the most active compound effectively inhibited the proliferation of CRC cell lines while shown little impact on normal colon epithelial cells. Mechanism studies revealed that displayed bromodomain-containing protein 4 inhibitory activity, and induced G2/M phase arrest, apoptosis as well as decreased the expression levels of the key genes such as and in CRC cell lines. Moreover, the ADMET properties prediction results shown that possess well metabolic characteristics without obvious toxicities. Our data demonstrated that compound may be a promising anti-CRC agent and deserved for further development.
结直肠癌(CRC)是人类消化道常见的恶性肿瘤。CRC 死亡率高与其现有治疗方法的局限性密切相关。因此,迫切需要寻找新的抗 CRC 药物。在这项工作中,设计、合成并评估了二十种新型香豆素-二硫代氨基甲酸盐衍生物()。结果表明,最活跃的化合物 有效地抑制了 CRC 细胞系的增殖,而对正常结肠上皮细胞影响很小。机制研究表明, 表现出溴结构域蛋白 4 的抑制活性,并诱导 G2/M 期阻滞、细胞凋亡以及降低 CRC 细胞系中 和 等关键基因的表达水平。此外,ADMET 性质预测结果表明, 具有良好的代谢特性,没有明显的毒性。我们的数据表明,化合物 可能是一种有前途的抗 CRC 药物,值得进一步开发。